3 results
Approved WMOWill not start
To compare the progression-free survival (PFS) in subjects with pancreatic islet cell tumors treated with sunitinib at a starting dose of 37.5 mg daily (continuous dosing) with those treated with placebo.
Approved WMORecruiting
The primary objective is to determine whether micro-structured TCP granules provides sufficient bone volume as basis to insert endosseous dental implants in a two staged sinus floor elevation technique by benefiting from the clinical handling…
Approved WMORecruiting
To address whether the individualized fludarabine conditioning reduces the incidence of severe viral infections at day 100 within the context of an αβTCR / CD19 depleted transplantation regimen.